MIMasaoki Ito

Masaoki Ito

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Masaoki Ito has a total of 135 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Surgical and Pathological Outcomes of Non-Small-Cell Lung Cancer Patients Who Did Not Radiologically Respond to Neoadjuvant Chemo-Immunotherapy

    by Kenichi Suda, Taichi Matsubara, Masaoki Ito, Tomoyo Fukami, Akira Hamada, Miyuki Abe, Shuichi Shinohara, Kyoshiro Takegahara, Shinji Kaneda, Atsushi Ito, et al.

    Background: Neoadjuvant chemo-immunotherapy is now a standard treatment for resectable non-small cell lung cancer (NSCLC) patients with clinical stage II–III disease. However, some patients do not respond to the treatment radiologically, and the surgical and pathological outcomes in such patients remain unclear. Methods: We conducted a multi-institutional retrospective analysis of patients who received neoadjuvant chemo-immunotherapy at 29 centers in Japan (CReGYT-04 Neo-Venus study). In this study, we focused specifically on radiological non-responders to neoadjuvant chemo-immunotherapy. Results: Of 124 eligible patients, radiological responses indicated a complete/partial response (CR/PR) in 84, stable disease (SD) in 35, and progressive disease (PD) in 5 patients. Nine patients (five with PD, two with SD, and two with PR) did not undergo surgical resection, and one SD patient had exploratory thoracotomy. Surgical outcomes, including minimally invasive approach rates, procedures, operation time, blood loss, and postoperative complications, were similar between patients with SD and those with CR/PR. In the analysis of residual tumor classification, R0 resection was achieved in 88% of patients in the SD group and 98% of those in the CR/PR group. Accordingly, the odds of R1/R2 resection were higher in the SD group than in the CR/PR group (OR, 5.6; 95% CI, 0.8–65.3; p = 0.051). Among 31 SD patients with available pathological data, a major pathologic response (MPR) was achieved in 26%; in an exploratory analysis, pre-treatment PD-L1 status (p < 0.01) and a >50% decrease in the maximum standardized uptake value (SUVmax ratio < 50%) on FDG-PET/CT (p = 0.03) were associated with MPR. Conclusions: No statistically significant differences in surgical outcomes, including adverse events, were observed between the SD and CR/PR groups, while the odds of R1/R2 resection were higher in the SD group. Despite the absence of a radiological response, 26% of SD patients achieved MPR, highlighting the limitations of current image-based assessments in evaluating the efficacy of induction chemo-immunotherapy.

  • Open Access

    Circulating Tumor DNA-Based Molecular Residual Disease in Early-Stage Non-Small-Cell Lung Cancer: Biology, Assays, and the Path Toward MRD-Guided Care

    by Rajan Yadav, Masaoki Ito, Hideki Ujiie, Shuta Ohara, Yasuhiro Tsutani, Goutham Sunny

    Complete surgical resection remains the cornerstone of curative therapy for early-stage non-small-cell lung cancer (NSCLC), yet a substantial proportion of patients relapse despite a macroscopically complete operation and negative conventional staging. This residual risk reflects micrometastatic disease that is below the resolution of computed tomography and that current clinicopathologic risk factors only coarsely predict. Circulating tumor DNA (ctDNA) provides a direct, blood-based readout of this molecular residual disease (MRD), its detection after definitive treatment is among the strongest known predictors of recurrence, and ctDNA frequently rises months before radiographic progression. In this narrative review, based on a literature search closed on 12 September 2026, we synthesize the foundational and translational literature underpinning ctDNA-MRD in resected NSCLC. We outline the biology of ctDNA shedding and metastatic dissemination established by serial-sampling and phylogenetic studies; the prognostic performance of landmark and longitudinal MRD, tabulated quantitatively across the major cohorts, meta-analyses and trial-nested analyses; the perioperative kinetics that dictate when sampling is informative; the analytical design of tumor-informed versus tumor-agnostic assays and the determinants of their sensitivity; and the biological and technical sources of false-negative and false-positive results, of which clonal hematopoiesis and low-shedding histologies are the most consequential. We then position MRD within the contemporary perioperative treatment landscape—adjuvant targeted therapy and immunotherapy, and neoadjuvant and perioperative chemoimmunotherapy—and review the emerging, still-investigational paradigm of MRD-guided escalation and de-escalation, including the early termination of the MRD-selected MERMAID trials. We conclude with the analytical, evidentiary and implementation barriers—and the current positions of guideline bodies and regulators—that separate a powerful prognostic biomarker from a validated predictive tool, and we set out the trial-design requirements needed to close that gap.

  • Open Access

    A Computational Histology Artificial Intelligence Prognostic Biomarker in Non-Small Cell Lung Cancer Using the Cancer Genome Atlas

    by Benjamin A. Bleiberg, Masaoki Ito, Melina Marmarelis, Viswesh Krishna, Vivek Nimgaonkar, Haochen Zhang, Trevor J. Royce, Yasuhiro Tsutani, David Kozono, Charu Aggarwal

    Background/Objectives: Outcomes in non–small cell lung cancer (NSCLC) remain heterogeneous, even within stage and molecular subtypes. We evaluated whether a Computational Histology Artificial Intelligence (CHAI) biomarker, derived solely from the diagnostic hematoxylin-and-eosin (H&E) whole-slide image (WSI), provides prognostic information independent of established clinicopathologic factors. Methods: Using The Cancer Genome Atlas (TCGA) lung adenocarcinoma (LUAD) and lung squamous cell carcinoma (LUSC) projects, 914 patients with an evaluable diagnostic digitized whole-slide images (WSI) and outcomes data were stratified by stage and histology and randomly split into a development set (30%, N = 270) and a held-out validation set (70%, N = 644). A CHAI histologic signature was developed and locked on the development set and applied without modification to the validation set. In development, image features were extracted from H&E-stained WSIs and used to train a Cox proportional hazards model to output a CHAI prognostic biomarker score and then dichotomized into high (CHAI positive (+))- and low (CHAI negative (−))-risk groups. The primary endpoint was overall survival (OS), and the secondary endpoint was progression-free interval (PFI). Associations were assessed by Kaplan–Meier and Cox proportional-hazards models and adjusted for traditional clinicopathologic and genomic variables. Results: A total of 644 patients were included in the validation cohort. Median age was 68 (IQR: 60–74), 388 (60%) were male, 317 (49%) had LUAD, 327 (51%) had LUSC, and 57 (9%) were never smokers. CHAI-positive patients had significantly worse OS than CHAI-negative patients (3-year OS: 53% vs. 69%; log-rank p < 0.001). The biomarker remained significantly associated with OS (HR 1.70, 95% CI 1.29–2.24, p < 0.001) and PFI (HR 1.39, 95% CI 1.05–1.84, p = 0.023) in multivariable analysis. The effect was consistent across both histologies, and a model combining the CHAI score with clinicopathologic variables was well-calibrated in validation. The biomarker was not associated with stage, age, sex, or histologic subtype, and its adjusted prognostic effect was unchanged after relevant genomic alterations were added to the model. CHAI-positive tumors were, however, enriched for KRAS mutations (21% vs. 11% wild-type, p adjusted = 0.005). Conclusions: An H&E-only CHAI NSCLC biomarker was developed and provided independent prognostic stratification in a held-out NSCLC validation cohort. Such a biomarker has the potential to refine risk stratification in NSCLC.

  • Open Access

    Surgical and Pathological Outcomes of Lung Cancer Patients Who Did Not Radiologically Respond to Neoadjuvant Chemoimmunotherapy

    by Kenichi Suda, Taichi Matsubara, Masaoki Ito, Tomoyo Fukami, Akira Hamada, Miyuki Abe, Shuichi Shinohara, Kyoshiro Takegahara, Shinji Kaneda, Atsushi Ito, et al.

    Background: Neoadjuvant chemo-immunotherapy is now a standard treatment for resectable non-small cell lung cancer (NSCLC) patients with clinical stage II–III disease. However, some patients do not respond to the treatment radiologically, and the surgical and pathological outcomes in such patients remain unclear. Methods: We conducted a multi-institutional retrospective analysis of patients who received neoadjuvant chemo-immunotherapy at 29 centers in Japan (CReGYT-04 Neo-Venus study). In this study, we focused specifically on radiological non-responders to neoadjuvant chemoimmunotherapy. Results: Of 124 eligible patients, radiological responses indicated a complete/partial response (CR/PR) in 84, stable disease (SD) in 35, and progressive disease (PD) in 5 patients. Nine patients (five with PD, two with SD, and two with PR) did not undergo surgical resection, and one SD patient had exploratory thoracotomy. Surgical outcomes, including minimally invasive approach rates, procedures, operation time, blood loss, and postoperative complications, were similar between patients with SD and those with CR/PR. Among 31 SD patients with available pathological data, a major pathologic response (MPR) was achieved in 26%, and pre-treatment PD-L1 status (p<0.01) and a ≥50% decrease in the maximum standardized uptake value on FDG-PET/CT (p=0.03) were associated with MPR. Conclusions: Surgical outcomes were similar between the SD and CR/PR groups, and 26% of SD patients achieved MPR, supporting strategies that actively pursue surgical resection, even in radiological non-responders to neoadjuvant treatment.

  • Open Access

    Refining Surgical Standards: The Role of Robotic-Assisted Segmentectomy in Early-Stage Non-Small-Cell Lung Cancer

    by Masaya Nishino, Hideki Ujiie, Masaoki Ito, Hana Oiki, Shota Fukuda, Mai Nishina, Shuta Ohara, Akira Hamada, Masato Chiba, Toshiki Takemoto, et al.

    Background: Recent trials, including JCOG0802/WJOG4607L and CALGB140503, have confirmed the oncological adequacy of segmentectomy for early-stage non-small-cell lung cancer (NSCLC). This shift emphasizes the preservation of pulmonary function and minimal invasiveness. Robot-assisted thoracic surgery (RATS) offers enhanced anatomical precision and potentially improves segmentectomy outcomes. Methods: We reviewed the current evidence comparing sublobar resection and lobectomy for early-stage NSCLC, focusing on RATS segmentectomy. Clinical trials, perioperative and long-term outcomes, technical innovations, and patient selection criteria were analyzed. Comparative data among RATS, video-assisted thoracoscopic surgery (VATS), and open approaches were synthesized, including the emerging roles of AI and 3D imaging. Results: Segmentectomy yields survival outcomes equivalent or superior to lobectomy for stage IA peripheral NSCLC ≤2 cm, with better pulmonary function despite higher locoregional recurrence. RATS enhances visualization, dexterity, and ergonomics, thereby enabling precise dissection and lymph node assessment. Compared to VATS and open surgery, RATS shows lower conversion rates, reduced pain, and comparable oncological control. Innovations, such as indocyanine green imaging, 3D modeling, and AI-guided navigation, support margin accuracy and personalized care. Conclusions: Segmentectomy has redefined the surgical standards for early-stage NSCLC. RATS maximizes the minimally invasive benefits by combining oncological safety and functional preservation. Its technical precision facilitates complex resections and integration with digital planning tools to advance personalized thoracic surgery. RATS represents the next evolution of minimally invasive thoracic surgery, redefining the balance between oncological safety and functional preservation in early-stage NSCLC.


  • Open Access

    Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

    by Koichi Tomoshige, William D. Stuart, Iris M. Fink-Baldauf, Masaoki Ito, Tomoshi Tsuchiya, Takeshi Nagayasu, Tomoki Yamatsuji, Morihito Okada, Takuya Fukazawa, Minzhe Guo, et al.

    Supplementary Materials and Methods and Supplementary Figures

  • Open Access

    Supplementary Data from FOXA2 Cooperates with Mutant KRAS to Drive Invasive Mucinous Adenocarcinoma of the Lung

    by Koichi Tomoshige, William D. Stuart, Iris M. Fink-Baldauf, Masaoki Ito, Tomoshi Tsuchiya, Takeshi Nagayasu, Tomoki Yamatsuji, Morihito Okada, Takuya Fukazawa, Minzhe Guo, et al.

  • Open Access

    Refining Surgical Standards: The Role of Robotic-Assisted Segmentectomy in Early-Stage Non-Small Cell Lung Cancer

    by Masaya Nishino, Hideki Ujiie, Masaoki Ito, Hana Oiki, Shota Fukuda, Mai Nishina, Shuta Ohara, Akira Hamada, Masato Chiba, Toshiki Takemoto, et al.

    Background: Recent trials, including JCOG0802/WJOG4607L and CALGB140503, con-firmed the oncological adequacy of segmentectomy for early-stage non-small cell lung cancer (NSCLC). This shift emphasizes the preservation of pulmonary function and minimal invasiveness. Robot-assisted thoracic surgery (RATS) offers enhanced anatomi-cal precision and potentially improves segmentectomy outcomes. Methods: We reviewed the current evidence comparing sublobar resection and lobectomy for early-stage NSCLC, focusing on RATS segmentectomy. Clinical trials, perioperative and long-term outcomes, technical innovations, and patient selection criteria were analyzed. Comparative data among RATS, video-assisted thoracoscopic surgery (VATS), and open approaches were synthesized, including the emerging roles of AI and 3D imaging. Results: Segmentectomy yields survival outcomes equivalent or superior to lobectomy for stage IA peripheral NSCLC ≤2 cm, with better pulmonary function despite higher locoregional recurrence. RATS enhances visualization, dexterity, and ergonomics, thereby enabling precise dissec-tion and lymph node assessment. Compared to VATS and open surgery, RATS shows lower conversion rates, reduced pain, and comparable oncological control. Innovations, such as indocyanine green imaging, 3D modeling, and AI-guided navigation, support margin accuracy and personalized care. Conclusions: Segmentectomy has redefined the surgical standards for early-stage NSCLC. RATS maximizes the minimally invasive bene-fits by combining oncological safety and functional preservation. Its technical precision facilitates complex resections and integration with digital planning tools to advance per-sonalized thoracic surgery. RATS represents the next evolution of minimally invasive thoracic surgery, redefining the balance between oncological safety and functional preservation in early-stage NSCLC.

  • Open Access

    Efficacy of Conventional and Novel Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations—An In Vitro Study

    by Hana Oiki, Kenichi Suda, Akira Hamada, Toshio Fujino, Keiko Obata, Yoshihisa Kobayashi, Kazuko Sakai, Shota Fukuda, Shuta Ohara, Masaoki Ito, et al.

    Afatinib and osimertinib are current treatment options for non-small cell lung cancer (NSCLC) patients with uncommon epidermal growth factor receptor (EGFR) mutations, although their efficacy is limited. To explore potentially effective drugs for these patients, we evaluated the efficacy of conventional EGFR tyrosine kinase inhibitors (TKIs) and novel third-generation (3G) TKIs using in vitro models. Ba/F3 cells transformed with each of the five most frequent uncommon EGFR mutations, Del18 (delE709_T710insD), E709K, G719A, S768I, and L861Q, were used. The growth inhibitory effects of five novel 3G-TKIs, almonertinib, lazertinib, furmonertinib, rezivertinib, and befotertinib, in addition to currently available TKIs, were evaluated. We also explored for secondary resistant mutations to afatinib or osimertinib and TKIs that can overcome these resistances. Afatinib was active against all uncommon EGFR mutations tested. The 3G-TKIs were all active against the L861Q mutation and were inactive against the S768I mutation. Furmonertinib and befotertinib showed efficacy against exon 18 mutations (Del18, E709K, and G719A). In the acquired resistance models to afatinib or osimertinib, we found T790M or a novel T725M secondary mutation, respectively, both of which could be overcome by lazertinib. However, some afatinib-resistant cells acquired V769L/M secondary mutations that were refractory to all EGFR-TKIs tested. In conclusion, afatinib exhibited broad activity and some 3G-TKIs showed promising efficacy in the front-line setting. Lazertinib is a potential second-line option after acquisition of resistance to afatinib or osimertinib.


  • Open Access

    Efficacy of Novel Third-Generation Tyrosine Kinase Inhibitors for Uncommon EGFR Mutations – an In Vitro Study

    by Hana Oiki, Kenichi Suda, Akira Hamada, Toshio Fujino, Keiko Obata, Yoshihisa Kobayashi, Kazuko Sakai, Shota Fukuda, Shuta Ohara, Masaoki Ito, et al.

    Afatinib and osimertinib are current treatment options for NSCLC patients with uncommon EGFR mutations, although their efficacy is limited. To explore potentially effective drugs for these patients, we evaluated the efficacy of novel third-generation tyrosine kinase inhibitors (3G-TKIs) using in vitro models. Ba/F3 cells transformed with each of the five most frequent uncommon EGFR mutations, Del18 (delE709_T710insD), E709K, G719A, S768I, and L861Q, were used. The growth inhibitory effects of five novel 3G-TKIs, almonertinib, lazertinib, furmonertinib, rezivertinib, and befotertinib, in addition to currently available TKIs, were evaluated. Afatinib was active against all uncommon EGFR mutations tested. The 3G-TKIs were all active against the L861Q mutation and were inactive against the S768I mutation. Furmonertinib and befotertinib showed efficacy against exon 18 mutations (Del18, E709K, and G719A). In the acquired resistance models to afatinib or osimertinib, we found T790M or a novel T725M secondary mutation, respectively, both of which could be overcome by lazertinib. However, some afatinib-resistant cells acquired V769L/M secondary mutations that were refractory to all EGFR-TKIs tested. In conclusion, afatinib exhibited broad activity and some 3G-TKIs showed promising efficacy in the front-line setting. Lazertinib is a potential second-line option after acquisition of resistance to afatinib or osimertinib.